Latest gene delivery Stories
RICHMOND, Calif., June 19, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced the appointment of H. Stewart Parker to the Company's Board of Directors. Ms.
Company will draw on leaders' expertise in rare diseases, R&D and commercialization as it moves to complete development of its lead program in inherited blindness PHILADELPHIA, June
Staph infections that become resistant to multiple antibiotics don't happen because the bacteria themselves adapt to the drugs, but because of a kind of genetic parasite they carry called a plasmid that helps its host survive the antibiotics.
Barbara and Edward Netter awarded prestigious distinction by the American Society of Gene and Cell Therapy. Washington, DC (PRWEB) June 05, 2014 Barbara
PHILADELPHIA, June 2, 2014 /PRNewswire/ -- Spark Therapeutics, Inc., a late-stage gene therapy company developing treatments for a wide range of rare, debilitating diseases, announced today that company
Groundbreaking Nature Publication Describes Successful ZFN Driven Genome Editing in Long-Term Repopulating Stem Cells Necessary for Clinical Translation RICHMOND, Calif., May 28, 2014
Gene therapy leader to advance its deep pipeline of rare disease programs including its lead Phase 3 product candidate for RPE65-related blindness PHILADELPHIA, May 27, 2014 /PRNewswire/
SB-728-T-Treated Subject Maintains Control of Viral Load for 45 Weeks Without Anti-Retroviral Drugs RICHMOND, Calif., May 27, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc.
Transparency Market Research added a new report "Global Gene Therapy Market: Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store.
Researchers from Nexus Spine LLC and Brigham Young University have Developed New, High-Tech Device for Transferring DNA into Cells WASHINGTON, May 13, 2014 /PRNewswire-USNewswire/
- A poem in which the author retracts something said in an earlier poem.